IGF-1 LR3

IGF-1 LR3 is a synthetic analogue of the naturally occurring IGF-1 hormone with an arginine substitution at position 3 and 13 additional N-terminus amino acids. These modifications reduce binding-protein affinity, giving it a 20–30 hour half-life and ~3x the potency of native IGF-1. Uniquely, it drives muscle hypertrophy and fat oxidation simultaneously.

Binds IGF-1 receptors throughout muscle and adipose tissue, activating the PI3K/Akt/mTOR pathway to drive protein synthesis and satellite cell proliferation, while stimulating lipolysis in fat tissue. Post-workout timing leverages elevated muscle insulin sensitivity and GLUT4 upregulation for superior nutrient partitioning.

Muscle hypertrophy • Body composition • Recovery acceleration • Nutrient partitioning • Connective tissue support • Lean gain retention

Week 1: 20–40 mcg/day (2–4 units) tolerance assessment. Weeks 2–8: 60–80 mcg/day (6–8 units) maintenance. Once daily subcutaneous, post-workout preferred (within 30 minutes) or morning fasted on rest days. Never inject within 2 hours of bedtime. 8 weeks on / 8 weeks off.

Vial size: 1 mg (1000 mcg) Water volume: 1 mL bacteriostatic water Concentration: 10 mcg per unit (0.01 mg per unit) Add 1 mL of bacteriostatic water slowly along the vial wall — do not shake or agitate. 20mcg = 2u, 40mcg = 4u, 60mcg = 6u, 80mcg = 8u.

Before reconstitution: Store lyophilized powder at -20°C, protected from light. After reconstitution: Refrigerate immediately at 2–8°C. Use within 2–3 weeks. Significantly less stable than most peptides — do not leave out of the fridge. Some users aliquot to minimise freeze-thaw cycles.

Half-life: Approximately 20–30 hours. Stability: Lower solution stability than most peptides — strict refrigeration required. Hypoglycaemia risk: always inject post-meal, never fasted in the post-workout window. Contraindicated with active malignancy/cancer history, active diabetic retinopathy, and users under 25.